Merck
  • Home
  • Search Results
  • Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

Future oncology (London, England) (2013-11-15)
Nicoletta Colombo
ABSTRACT

Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity. In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
铂, wire, diam. 0.5 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, gauze, 100 mesh, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 1.0 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
铂黑, black, powder, ≤20 μm, ≥99.95% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.025 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.5 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
铂黑, fuel cell grade, ≥99.9% trace metals basis
Sigma-Aldrich
铂, gauze, 52 mesh, 99.9% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.05 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, powder, 99.995% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.1 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 2.0 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.076 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.125-0.135 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.10 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, powder (coarse), 99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.20 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.25 mm, thermocouple grade
Sigma-Aldrich
铂, nanopowder, 200 nm particle size (SEM), 99.9% (metals basis)
Sigma-Aldrich
铂, foil, thickness 0.5 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.025 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, sponge, ≥99.9% trace metals basis
铂, wire reel, 1m, diameter 0.001mm, wollaston, 99.9%
铂, foil, 25x25mm, thickness 0.125mm, as rolled, 99.99+%